Table 2.
An Overview on Nanomaterials-Based Electrochemical Methods for Exosome Detection
Methods | Type of Nanomaterials | Functions | Cancer Types | Target Biomarkers | Response Time (min) | Detection Limit (Particles/μL) | Linear Range (Particles/μL) | Ref. |
---|---|---|---|---|---|---|---|---|
Electrochemistry (direct detection) | AuNPs | Improving the large surface area, accelerating electrical conductivity and facilitating the immobilization of biorecognition elements | Breast cancer | CD63 | 180 | 4.82 × 102 | 5 × 102–5 × 103 | [181] |
BPNSs and MOFs | Breast cancer | CD63 | Not reported | 1 × 102 | 1.3 × 102–2.6 × 105 | [182] | ||
Electrochemistry (sandwich detection) | AuNPs | Nanocarriers for enzymes, electroactive molecules | Liver cancer | CD63 | 255 | 16.6 | 21.6–7.5 × 104 | [189] |
Zr-MOF | Glioblastoma | EGFR, EGFRvIII, and phosphate groups outside of exosomes | 150 | 7.83 × 103 | 9.5 × 103–1.9 × 107 | [190] | ||
Zr-MOF and ZIF-8 | Breast cancer | CD63 and phosphate groups outside of exosomes | 190 | 0.3 | 1–1 × 105 | [191] | ||
ZIF-8 | Breast cancer | CD63 and PD-L1 | 245 | 0.334 | 1–1 × 107 | [192] | ||
COFs@Au NPs | Colorectal cancer | CD63 and amino acid residues outside of exosomes | 170 | 1.6 × 102 | 5 × 102–5 × 107 | [193] | ||
Au-NPFe2O3NC | Nanozymes to catalyze the redox reaction | Placental choriocarcinoma | CD63 and PLAP | 90 | 1 | 1–1 × 104 | [194] | |
Ti3C2 MXene@PB | Showing electroactive properties or consisting of electroactive ions | Ovarian cancer | CD63 | 120 | 2.29 × 102 | 5 × 102–5.0 × 105 | [195] | |
CdSe QDs | Colorectal adenocarcinoma | CD63, HER-2 and FAM134B | 130 | 1 × 102 | 1 × 102–1 × 107 | [196] | ||
Electrochemiluminescence | Ru(II) markers-loaded SiNPs | Nanomaterials acts as nanocarriers for molecules | Hepatocellular carcinoma | CD63 | 120 | 60 | 2 × 102–7.5 ×104 | [212] |
CdS:Eu QDs | Electrochemiluminescence emitter | Breast cancer | CD63 | 240 | 74.1 | 3.4 × 102–1.7 × 104 | [210] | |
CdS QDs@CaCO3 | Breast cancer | EpCAM | 180 | 21 | 50–1 × 105 | [212] | ||
g-C3N4@Galinstan-PDA | Cervical cancer | GPC-1 | 120 | 31 | 50–1 × 105 | [211] | ||
BPQDs@ Ti3C2 MXene | Coreactants | Breast cancer | CD63 and EpCAM | 100 | 37 | 1.1 × 102–1.1 × 107 | [214] | |
AuNPs@ Ti3C2 MXene | Nanocatalysts | Cervical cancer | CD63 | 240 | 30 | 1 × 102–1 × 105 | [215] | |
Ti3C2 MXene | Breast cancer | EpCAM | 240 | 1.25 × 102 | 5 × 102–5 × 106 | [213] | ||
AuNPs@ g-C3N4 | Ovarian cancer | phosphatidylserine | 120 | 39 | 1 × 102–1 × 107 | [216] |
Abbreviations: BPNSs, black phosphorus nanosheets; AuNPs, gold nanoparticles; MOFs, metal organic frameworks; COFs, covalent organic frameworks; Au-NPFe2O3NC, gold-loaded ferric oxide nanocubes; PB, Prussian blue; QDs, quantum dots; PDA, polydopamine; BPQDs, black phosphorus quantum dots; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant (v) III mutation; PD-L1, programmed death ligand-1; PLAP, placental alkaline phosphatase; EpCAM, epithelial cell adhesion molecule; GPC-1, glypican-1.